ADC Therapeutics (ADCT) Capital Expenditures (2020 - 2026)
ADC Therapeutics (ADCT) posted Capital Expenditures of $32000.0 for Q1 2026, down 87.88% sequentially from $264000.0 in Q1 2025, and down 87.88% YoY from $264000.0 in Q1 2025.
ADC Therapeutics (ADCT) Capital Expenditures (2020 - 2026) Analysis & Trends
ADC Therapeutics has reported Capital Expenditures for 7 years, with the latest figure at $32000.0 in Q1 2026.
- Quarterly Capital Expenditures fell 87.88% year-over-year to $32000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32000.0 (down 94.67% YoY) and the FY2025 annual result came in at $264000.0, down 69.55% from the prior year.
- Capital Expenditures declined to $32000.0 in Q1 2026 per ADCT's latest filing, from $264000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $1.2 million in Q2 2023 and troughed at $30000.0 in Q2 2024.
- A 5-year average of $361857.1 and a median of $222500.0 in 2022 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2023 and 2024: Capital Expenditures jumped 2324.0% in 2023, then slumped 97.52% in 2024.
- Over 5 years, Capital Expenditures stood at $214000.0 in 2022, then surged by 52.8% to $327000.0 in 2023, then sank by 72.48% to $90000.0 in 2024, then surged by 193.33% to $264000.0 in 2025, then sank by 87.88% to $32000.0 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $32000.0, $264000.0, and $90000.0 for Q1 2026, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.97 Bn | 132.12 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 86.64 Bn | 78.64 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 65.55 Bn | 60.37 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.26 Bn | 56.12 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 42.30 Bn | 37.20 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.66 Bn | 28.35 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.68 Bn | 10.29 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 251.02 Mn |
| 10 | ADC Therapeutics | 152.04 Mn | -67.07 Mn | 17.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32,000.00 |
| Mar 31, 2026 | 32,000.00 |
| Mar 31, 2025 | 264,000.00 |
| Mar 31, 2025 | 264,000.00 |
| Dec 31, 2024 | 90,000.00 |
| Dec 31, 2024 | 90,000.00 |
| Sep 30, 2024 | 216,000.00 |
| Sep 30, 2024 | 216,000.00 |
| Jun 30, 2024 | 30,000.00 |
| Jun 30, 2024 | 30,000.00 |
| Mar 31, 2024 | 531,000.00 |
| Mar 31, 2024 | 531,000.00 |
| Dec 31, 2023 | 327,000.00 |
| Dec 31, 2023 | 327,000.00 |
| Sep 30, 2023 | 661,000.00 |
| Sep 30, 2023 | 661,000.00 |
| Jun 30, 2023 | 1.21 Mn |
| Jun 30, 2023 | 1.21 Mn |
| Mar 31, 2023 | 1.02 Mn |
| Mar 31, 2023 | 1.02 Mn |